[1] Qamar AA, Grace ND, Groszmann RJ, et al. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol, 2009,7:689-695.
[2] Sanjo A, Satoi J, Ohnishi A, et al. Role of elevated platelet-associated immunoglobulin G and hypersplenism in thrombocytopenia of chronic liver diseases. J Gastroenterol Hepatol, 2003,18:638-644.
[3] Feng Y, Li X, Xiao J, et al. ADAMTS13: more than a regulator of thrombosis. Int J Hematol, 2016,104:534-539.
[4] Sinegre T, Duron C, Lecompte T, et al. Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis. J Thromb Haemost, 2018,16:1132-1140.
[5] Martinez J, MacDonald KA, Palascak JE. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Blood, 1983,61:1196-1202.
[6] Ogasawara F, Fusegawa H, Haruki Y, et al. Platelet activation in patients with alcoholic liver disease. Tokai J Exp Clin Med, 2005,30:41-48.
[7] Ambrosino P, Tarantino L, Di Minno G, et al. The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis. Thromb Haemost, 2017,117:139-148.
[8] Rassi AB, d'Amico EA, Tripodi A, et al. Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: Effect on conventional coagulation tests and thrombomodulin-modified thrombin generation. J Hepatol, 2020,72:85-94.
[9] Rijken DC, Kock EL, Guimaraes AH, et al. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost, 2012,10:2116-2122.
[10] Rossetto V, Spiezia L, Senzolo M, et al. Does decreased fibrinolysis have a role to play in the development of non- neoplastic portal vein thrombosis in patients with hepatic cirrhosis? Intern Emerg Med, 2014, 9:397-403. |
